GOSSELIES, Belgium--(BUSINESS WIRE)--Ncardia has launched a new business, Cellistic™, to focus Ncardia’s induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector. This strategy expands on Ncardia’s existing drug discovery solutions business and capitalizes on the company’s deep expertise in iPSC differentiation and expansion to focus dedicated resources and capabilities to address the growing need for iPSC cell therapy solutions, including the development of robust cell-specific manufacturing platforms.
LEIDEN, The Netherlands--(BUSINESS WIRE)--Ncardia, the leader in developing stem cell-based solutions for drug discovery and cell therapy, announced today the appointment of Andy Holt as Chief Commercial Officer.
A Belgian cell therapy company has secured $60 million in funding to strengthen its manufacturing operations, and grow the cell and gene therapy ecosystem across the world.